PCRX

Pacira Biosciences Stock Analysis

AI Rating

Neutral
  • Quality9/10
  • Growth 5/10
  • Momentum 3/10
Pacira Biosciences sales and earnings growth
PCRX Growth
Neutral
  • Revenue Y/Y 3.14%
  • EPS Y/Y 123.35%
  • FCF Y/Y -35.82%
Pacira Biosciences gross and profit margin trends
PCRX Profitability
Neutral
  • Gross margin 79.20%
  • EPS margin 3.00%
  • ROIC 5.30%
Pacira Biosciences net debt vs free cash flow
PCRX Risk
Great
  • Debt / Equity 0.6
  • Debt / FCF 2.2
  • Interest coverage 3.3

Pacira Biosciences stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Drug Manufacturers - Specialty & Generic stocks ↗